152 related articles for article (PubMed ID: 36613940)
41. Expression of Autophagy-Related Proteins in Different Types of Thyroid Cancer.
Kim HM; Kim ES; Koo JS
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257096
[TBL] [Abstract][Full Text] [Related]
42. Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts.
Wallander M; Layfield LJ; Jarboe E; Emerson L; Liu T; Thaker H; Holden J; Tripp S
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):231-5. PubMed ID: 20042852
[TBL] [Abstract][Full Text] [Related]
43. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
Afkhami M; Karunamurthy A; Chiosea S; Nikiforova MN; Seethala R; Nikiforov YE; Coyne C
Thyroid; 2016 Feb; 26(2):242-7. PubMed ID: 26422023
[TBL] [Abstract][Full Text] [Related]
44. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
45. Presence of the BRAF V600E point mutation in morphologically benign appearing thyroid inclusions of cervical lymph nodes.
Mojica WD; Khoury T
Endocr Pathol; 2006; 17(2):183-9. PubMed ID: 17159251
[TBL] [Abstract][Full Text] [Related]
46. Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma.
Eloy C; Santos J; Soares P; Sobrinho-Simões M
Virchows Arch; 2011 Dec; 459(6):595-605. PubMed ID: 22081104
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg.
Rendl G; Rodrigues M; Schweighofer-Zwink G; Hutter J; Hittmair A; Zellinger B; Hauser-Kronberger C; Pirich C
Wien Klin Wochenschr; 2017 Aug; 129(15-16):540-544. PubMed ID: 28493027
[TBL] [Abstract][Full Text] [Related]
48. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
49. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
[TBL] [Abstract][Full Text] [Related]
50. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.
Lim JY; Hong SW; Lee YS; Kim BW; Park CS; Chang HS; Cho JY
Thyroid; 2013 Nov; 23(11):1423-30. PubMed ID: 23496275
[TBL] [Abstract][Full Text] [Related]
51. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
52. BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features.
Proietti A; Giannini R; Ugolini C; Miccoli M; Fontanini G; Di Coscio G; Romani R; Berti P; Miccoli P; Basolo F
Thyroid; 2010 Nov; 20(11):1263-70. PubMed ID: 20950194
[TBL] [Abstract][Full Text] [Related]
53. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
54. [Use of BRAF V600E mutation in the differential diagnosis of follicular and papillary tumors of the thyroid and for the optimization of thearpy].
Semënov DIu; Boriskova ME; Zaraĭskiĭ MI; Saburova IIu; Pankova PA; Farafonova UV; Bykov MA
Vopr Onkol; 2012; 58(5):649-52. PubMed ID: 23600282
[TBL] [Abstract][Full Text] [Related]
55. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
Gao WL; Wie LL; Chao YG; Wie L; Song TL
Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
[TBL] [Abstract][Full Text] [Related]
56. Papillary thyroid carcinoma with extensive squamous dedifferentiation metastatic to the lung: BRAF mutational analysis as a useful tool to rule out tumor to tumor metastasis.
Acosta AM; Pins MR
Virchows Arch; 2016 Feb; 468(2):239-42. PubMed ID: 26521063
[TBL] [Abstract][Full Text] [Related]
57. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
58. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
[TBL] [Abstract][Full Text] [Related]
59. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
[TBL] [Abstract][Full Text] [Related]
60. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]